Which company’s drug information is Teclistamab?

Teritusumab (Teclistamab-cqyv) is an innovative bispecific antibody drug developed and produced by Johnson & Johnson (Janssen Biotech Inc.). The drug was approved by the FDA in the United States in 2022 for the treatment of patients with relapsed or refractory multiple myeloma (MM). Its research and development concept is based on the reactivation mechanism of the immune system, achieving precise immune targeted killing by connecting the CD3 receptor on the surface of T cells with the BCMA (B cell maturation antigen) receptor on the surface of myeloma cells. This design allows the patient's own immune system to re-recognize and eliminate tumor cells, becoming an important breakthrough in the field of anti-myeloma treatment.

As the world's first approved BCMA/CD3 bispecific antibody drug, teritusumab brings new hope to patients who have failed to respond to traditional drug treatments. It is different from conventional chemotherapy or monoclonal antibody drugs, but uses the body's immune mechanism to directly intervene in the tumor cell clearance process. Janssen positions it as a core member of "next generation immune cell-directed therapies" in its global drug pipeline. The drug has also been approved by the European Medicines Agency (EMA) and some Asian countries, demonstrating its international clinical value and safety recognition.

Currently, teritusumab is mainly administered as a subcutaneous injection to facilitate administration and reduce infusion-related reactions. Due to its strong immune activity, early treatment needs to be carried out under the supervision of a medical institution. As more studies are conducted, Johnson & Johnson is also exploring its combination with other myeloma drugs, such as lenalidomide, pomalidomide or proteasome inhibitors, in order to further improve efficacy and prolong remission time. Overall, the launch of teritolumab marks a new stage in immunotherapy for multiple myeloma and provides new ideas for long-term disease management.

Reference materials:https://www.tecvayli.com/